Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-UOM-CAP-21-04-2015-13:03:14:947-502 - samples

ABSTRACT: Data from the study of subclonal metastatic expansion in prostate cancer. Whole genome shotgun sequencing of fifteen samples, tumour and whole blood, from the four initial patients.

PROVIDER: EGAD00001001343 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

Hong Matthew K H MK Macintyre Geoff G Wedge David C DC Van Loo Peter P Patel Keval K Lunke Sebastian S Alexandrov Ludmil B LB Sloggett Clare C Cmero Marek M Marass Francesco F Tsui Dana D Mangiola Stefano S Lonie Andrew A Naeem Haroon H Sapre Nikhil N Phal Pramit M PM Kurganovs Natalie N Chin Xiaowen X Kerger Michael M Warren Anne Y AY Neal David D Gnanapragasam Vincent V Rosenfeld Nitzan N Pedersen John S JS Ryan Andrew A Haviv Izhak I Costello Anthony J AJ Corcoran Niall M NM Hovens Christopher M CM

Nature communications 20150401

Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. However, how the subclonal diversity of tumours changes during metastasis and progression to lethality is poorly understood. Here we reveal the precise direction of metastatic spread across four lethal prostate cancer patients using whole-genome and ultra-deep targeted sequencing of longitudinally collected primary and metastatic tumours. We find one case of metastatic spread to the surgical bed causing local recur ...[more]

PMID: 25827447

Similar Datasets

ena-DATASET-UOM-CAP-21-04-2015-13:04:36:707-504 - samples

Project description:Data from the study of subclonal metastatic expansion in prostate cancer. Whole genome shotgun sequencing of six samples, tumour and whole blood, from the three additional patients whose somatic variants were examined in depth.

| EGAD00001001344 | EGA

ena-DATASET-UOM-CAP-21-04-2015-13:06:47:615-508 - samples

Project description:Data from the study of subclonal metastatic expansion in prostate cancer. RNA-seq of twelve samples, tumour and benign tissue, from the four initial patients.

| EGAD00001001345 | EGA

21 Breast Cancer Genome Affymetrix SNP6 Array Data

Project description:Cancer evolves dynamically, as clonal expansions supersede or overlap one another, driven by shifting selective pressures, mutational processes and disrupted cancer genes. These processes mark the genome, such that a cancerÕs life history is encrypted in the timing, ploidy, clonality and patterns of somatic mutation. We developed bioinformatic algorithms to decipher this narrative, and applied them to 21 breast cancer genomes. We find that mutational processes evolve across the lifespan of a breast tumor, with cancer-specific signatures of point mutations and chromosomal instability often emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, providing insight into the dynamics of clonal expansion in breast cancer. Most point mutations are found in just a fraction of tumor cells, together with frequent variegation in chromosomal copy number. Every tumor studied here has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent lineages of cells that are capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.

2012-06-16 | E-MTAB-1087 | biostudies-arrayexpress

DENDRO: genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing

Project description:We delineate subclonal expansion in a mouse melanoma models in response to immunotherapy, highlighting the role of neoantigens

2019-11-10 | GSE139248 | GEO

17 Breast Cancer Genome Illumina Expression Data

2012-06-29 | E-MTAB-1088 | biostudies-arrayexpress

KMT2A-rearranged leukemia proteomics

Project description:Activating mutations in kinase/PI3K/RAS signaling pathways are common in acute leukemia with KMT2A rearrangements (KMT2A-R). These mutations are often subclonal and their biological impact remain unclear. Using a retroviral acute myeloid leukemia model, we demonstrate that NRASG12D, FLT3ITD, and FLT3N676K accelerates KMT2A-MLLT3 leukemia onset. Importantly, also the presence of subclonal FLT3N676K in KMT2A-R leukemic cells shorten disease latency, possibly by providing stimulatory factors such as Mif. Acquired de novo mutations in Braf, Cbl, Kras, and Ptpn11 were identified in KMT2A-MLLT3 driven leukemia and favored clonal expansion. KMT2A-MLLT3 leukemia with an activating mutation enforce Myc- and Myb transcriptional modules, whereas KMT2A-MLLT3 leukemias lacking activating mutations displayed upregulation of signal transduction pathways. Our results provide new insight into the biology of KMT2A-R leukemia and highlights the importance of activated signaling as a contributing driver in this disease.

2018-05-02 | PXD008213 | Pride

Biomphalaria glabrata strain:13-16-R1

Project description:Biomphalaria glabrata initial linkage map

| PRJNA288880 | ENA

Project description:Breast Tumors Maintain a Reservoir of Subclonal Diversity During Primary Expansion

| PRJNA629885 | ENA

Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression [cell lines]

Project description:Chronic inflammation is known to associate with prostate cancer development, but how epithelium-associated cancer initiating events cross-talk to inflammatory cells during prostate cancer initiation and progression is largely unknown. Using the Pten null murine prostate cancer model, we show an expansion of Gr-1+CD11b+ myeloid-derived suppressor cells (MDSCs) occurring intra-prostatically immediately following epithelium-specific Pten deletion without expansion in hematopoietic tissues. This MDSC expansion is accompanied by sustained immune suppression. Prostatic Gr-1+CD11b+ cells, but not those isolated from the spleen of the same tumor bearing mice, suppress T cell proliferation and express high levels of Arginase 1 and iNOS. Mechanistically, loss of PTEN in the epithelium leads to a significant upregulation of genes within the inflammatory response and cytokine-cytokine receptor interaction pathways, including Csf-1 and IL-1β, two genes known to induce MDSC expansion and immunosuppressive activities. Treating Pten null mice with the selective CSF-1 receptor inhibitor GW2580 decreases MDSC infiltration and relieves the associated immunosuppressive phenotype. Our study indicates that epithelium-associated tumor initiating events trigger the secretion of inflammatory cytokines and promote localized MDSC expansion and immune suppression, thereby promoting tumor progression Custom Agilent 4x44K whole mouse genome expression oligonucleotide microarrays were used to measure transcript levels in murine Pten null prostate cancer cell lines. Benign mouse prostate epithelia as wild type control against cell lines. Each cohort had three biological replicates.

2014-04-03 | E-GEOD-56468 | biostudies-arrayexpress

Project description:Whole-genome sequencing of fifteen novel Paenibacillus strains

| PRJNA1468455 | ENA